Q0518 — Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 90-days
Q0518 is a HCPCS Level II code for pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 90-days. It belongs to the Temporary Codes section. It was terminated on December 31, 2024 and is not valid on new claims.
This code has been terminated
CMS terminated Q0518 on December 31, 2024. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for Q0518
- Long descriptor
- Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 90-days
- Short descriptor
- Supply fee hiv prep oral 90
- Added
- January 2, 2024
- Terminated
- December 31, 2024
- BETOS
- O1E
- Pricing indicator
- 46 — DMEPOS
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Carrier priced — not otherwise classified, individual determination, carrier discretion, or gap-filled amounts.
Codes adjacent to Q0518
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If Q0518 is not quite right, the correct code is very often within a few positions of it.
- Q0510Pharmacy supply fee for initial immunosuppressive drug(s), first month following transplant
- Q0511Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period
- Q0512Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period
- Q0513Pharmacy dispensing fee for inhalation drug(s); per 30 days
- Q0514Pharmacy dispensing fee for inhalation drug(s); per 90 days
- Q0515Injection, sermorelin acetate, 1 microgram
- Q0516Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 30-daysterminated
- Q0517Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 60-daysterminated
- Q0519Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 30-daysterminated
- Q0520Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 60-daysterminated
- Q0521Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription
- Q1004New technology intraocular lens category 4 as defined in federal register notice
- Q1005New technology intraocular lens category 5 as defined in federal register notice
- Q2004Irrigation solution for treatment of bladder calculi, for example renacidin, per 500 ml
- Q2009Injection, fosphenytoin, 50 mg phenytoin equivalent
- Q2017Injection, teniposide, 50 mgterminated
Questions about Q0518
What is HCPCS code Q0518?
Q0518 is a HCPCS Level II code for pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 90-days. It sits in the Temporary Codes section.
Does Medicare cover Q0518?
The CMS HCPCS file marks Q0518 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is Q0518 still valid?
No. Q0518 was terminated on December 31, 2024 and should not be used on new claims.